- Home
- NCPL vs BOLT Comparison
NCPL vs BOLT Comparison
Compare NCPL & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCPL
- BOLT
- Stock Information
- Founded
- NCPL 1984
- BOLT 2015
- Country
- NCPL United States
- BOLT United States
- Employees
- NCPL N/A
- BOLT N/A
- Industry
- NCPL Investment Managers
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- NCPL Finance
- BOLT Health Care
- Exchange
- NCPL Nasdaq
- BOLT Nasdaq
- Market Cap
- NCPL 9.1M
- BOLT 9.4M
- IPO Year
- NCPL N/A
- BOLT 2021
- Fundamental
- Price
- NCPL $2.34
- BOLT $5.18
- Analyst Decision
- NCPL
- BOLT Buy
- Analyst Count
- NCPL 0
- BOLT 3
- Target Price
- NCPL N/A
- BOLT $47.50
- AVG Volume (30 Days)
- NCPL 205.7K
- BOLT 12.6K
- Earning Date
- NCPL 09-11-2025
- BOLT 11-11-2025
- Dividend Yield
- NCPL N/A
- BOLT N/A
- EPS Growth
- NCPL N/A
- BOLT N/A
- EPS
- NCPL N/A
- BOLT N/A
- Revenue
- NCPL $869,460.00
- BOLT $4,167,000.00
- Revenue This Year
- NCPL $739.37
- BOLT N/A
- Revenue Next Year
- NCPL N/A
- BOLT N/A
- P/E Ratio
- NCPL N/A
- BOLT N/A
- Revenue Growth
- NCPL N/A
- BOLT N/A
- 52 Week Low
- NCPL $1.41
- BOLT $4.59
- 52 Week High
- NCPL $8.75
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- NCPL 49.13
- BOLT 47.14
- Support Level
- NCPL $1.77
- BOLT $5.00
- Resistance Level
- NCPL $2.34
- BOLT $5.50
- Average True Range (ATR)
- NCPL 0.19
- BOLT 0.23
- MACD
- NCPL 0.11
- BOLT 0.04
- Stochastic Oscillator
- NCPL 74.03
- BOLT 53.69
About NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.